Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377936 | 1.00 | TGFBR1 (0.44) | TGFBR1TDP1RXFP1ALDH1A1KDM4E | |
| SCHEMBL28385316 | 0.84 | TDP1 (0.36) | TGFBR1TDP1RXFP1 | |
| SCHEMBL10543946 | 0.81 | TGFBR1 (0.47) | TGFBR1TDP1RXFP1ALDH1A1KDM4E | |
| SCHEMBL5451737 | 0.80 | CA14 (0.43) | TGFBR1TDP1RXFP1ALDH1A1KDM4E | |
| SCHEMBL5497463 | 0.80 | CA14 (0.43) | TGFBR1TDP1RXFP1ALDH1A1KDM4E | |
| SCHEMBL28665161 | 0.79 | TGFBR1 (0.39) | TGFBR1TDP1RXFP1 | |
| SCHEMBL149929 | 0.79 | TGFBR1 (0.55) | TGFBR1RXFP1ALDH1A1KDM4E | |
| SCHEMBL8518825 | 0.79 | TGFBR1 (0.55) | TGFBR1RXFP1ALDH1A1KDM4E | |
| SCHEMBL13952748 | 0.79 | TGFBR1 (0.50) | TGFBR1TDP1RXFP1ALDH1A1KDM4E | |
| SCHEMBL865671 | 0.79 | TGFBR1 (0.55) | TGFBR1RXFP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-06-18 | — | — | US | claimed |
| WO-2009055306-A2 | COATING DESIGNS FOR THE TAILORED RELEASE OF DUAL DRUGS FROM POLYMERIC COATINGS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20170348275-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-12-07 | — | — | US | disclosed |
| US-9763911-B2 | Prostacyclin compositions for regulation of fracture repair and bone formation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-06-18 | — | — | US | disclosed |
| EP-2668039-B1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2015-06-03 | — | — | EP | disclosed |
| US-8658749-B2 | Methods for manufacturing amino acid mimetic copolymers and use of same | ABBOTT LABORATORIES (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130298792-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| US-20130298792-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| US-8569435-B2 | Amino acid mimetic copolymers and medical devices coated with the copolymers | ABBOTT LABORATORIES (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569435-B2 | Amino acid mimetic copolymers and medical devices coated with the copolymers | ABBOTT LABORATORIES (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100183798-A1 | METHODS FOR MANUFACTURING AMINO ACID MIMETIC COPOLYMERS AND USE OF SAME | ABBOTT LABORATORIES | 2010-07-22 | — | — | US | disclosed |
| US-20100022663-A1 | METHODS FOR MANUFACTURING AMINO ACID MIMETIC COPOLYMERS AND USE OF SAME | ABBOTT LABORATORIES | 2010-01-28 | — | — | US | disclosed |
| US-7622537-B2 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622537-B2 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2009055306-A2 | COATING DESIGNS FOR THE TAILORED RELEASE OF DUAL DRUGS FROM POLYMERIC COATINGS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20080125514-A1 | Biocompatible polymers that include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers, the amino acid mimetic monomers being selected to mimic the side chain of the amino acids asparagine or glutamine; mechanical strength, drug permeability | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080124450-A1 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125514-A1 | Biocompatible polymers that include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers, the amino acid mimetic monomers being selected to mimic the side chain of the amino acids asparagine or glutamine; mechanical strength, drug permeability | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080124450-A1 | copolymerizing an amino acid mimetic monomer and hydrophobic acrylate monomers; amino acid mimetic monomers selected to mimic the side chain of the amino acids Asn or gln can be a (meth)acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide; biocompatible; coated stent | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | PTGIR, PTGIS, PTGS1 | TGFBR1 617/4885TDP1 2544/4885RXFP1 458/4885 |
| US-20170348275-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | PTGIR, PTGIS, PTGS1 | TGFBR1 617/4885TDP1 2544/4885RXFP1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.